<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="brief-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Trop. Dis</journal-id>
<journal-title>Frontiers in Tropical Diseases</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Trop. Dis</abbrev-journal-title>
<issn pub-type="epub">2673-7515</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fitd.2021.788188</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Tropical Diseases</subject>
<subj-group>
<subject>Perspective</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>Sharia</italic> (Islamic Law) Perspectives of COVID-19 Vaccines</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mardian</surname>
<given-names>Yan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1310620"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shaw-Shaliba</surname>
<given-names>Kathryn</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1251114"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karyana</surname>
<given-names>Muhammad</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1310672"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lau</surname>
<given-names>Chuen-Yen</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/617082"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Indonesia Research Partnership on Infectious Disease (INA-RESPOND)</institution>, <addr-line>Jakarta</addr-line>, <country>Indonesia</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>National Institute of Allergy and Infectious Diseases, National Institutes of Health</institution>, <addr-line>Bethesda, MD</addr-line>, <country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>National Institute of Health Research and Development, Ministry of Health, Republic of Indonesia</institution>, <addr-line>Jakarta</addr-line>, <country>Indonesia</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health</institution>, <addr-line>Bethesda, MD</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Son H. Nghiem, Griffith University, Australia</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Abhay Machindra Kudale, Savitribai Phule Pune University, India; Melvin Sanicas, Takeda Pharmaceutical International, Switzerland</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Yan Mardian, <email xlink:href="mailto:ymardian@ina-respond.net">ymardian@ina-respond.net</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Disease Prevention and Control Policy, a section of the journal Frontiers in Tropical Diseases</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>2</volume>
<elocation-id>788188</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>10</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Mardian, Shaw-Shaliba, Karyana and Lau</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Mardian, Shaw-Shaliba, Karyana and Lau</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The Coronavirus disease 2019 (COVID-19) pandemic has caused health, economic, and social challenges globally. Under these circumstances, effective vaccines play a critical role in saving lives, improving population health, and facilitating economic recovery. In Muslim-majority countries, Islamic jurisprudence, which places great importance on sanctity and safety of human life and protection of livelihoods, may influence vaccine uptake. Efforts to protect humans, such as vaccines, are highly encouraged in Islam. However, concerns about vaccine products&#x2019; <italic>Halal</italic> (permissible to consume by Islamic law) status and potential harm can inhibit acceptance. Fatwa councils agree that vaccines are necessary in the context of our current pandemic; receiving a COVID-19 vaccination is actually a form of compliance with Sharia law. Broader use of animal component free reagents during manufacturing may further increase acceptance among Muslims. We herein explain the interplay between <italic>Sharia</italic> (Islamic law) and scientific considerations in addressing the challenge of COVID-19 vaccine acceptance, particularly in Muslim populations.</p>
</abstract>
<kwd-group>
<kwd>Halal certificate</kwd>
<kwd>
<italic>Sharia</italic> (Islamic law)</kwd>
<kwd>Fatwa</kwd>
<kwd>COVID-19 vaccines</kwd>
<kwd>islamic</kwd>
</kwd-group>
<contract-sponsor id="cn001">Ministry of Health of the Republic of Indonesia<named-content content-type="fundref-id">10.13039/501100017022</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">National Institute of Allergy and Infectious Diseases<named-content content-type="fundref-id">10.13039/100000060</named-content>
</contract-sponsor>
<counts>
<fig-count count="0"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="45"/>
<page-count count="8"/>
<word-count count="4826"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>COVID-19, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, ignited a pandemic in 2020 and continues to circulate. Elevations in case numbers, circulation of variants of concern and potential variants of high consequence have alarmed the world. A coordinated global response led to development of COVID-19 vaccines in record time. Major vaccination efforts are now ongoing throughout the world (<xref ref-type="bibr" rid="B1">1</xref>). Unfortunately, uptake has been hindered for several reasons, including religious beliefs (<xref ref-type="bibr" rid="B2">2</xref>). This article will provide an Islamic perspective on COVID-19 vaccines.</p>
<p>In Islam, every aspect of life should align with <italic>Sharia</italic> (Islamic law), or God&#x2019;s will for humankind. The sources of Sharia are the <italic>Al-Quran</italic> (Islamic holy book) and <italic>Al-Hadith</italic> (record of the words, actions, and the silent approval of the Islamic Prophet Muhammad) (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). To effectuate God&#x2019;s will, Islamic scholars provide their interpretation through the Islamic body of law called <italic>Fiqh</italic> (Islamic jurisprudence). While <italic>Sharia</italic> is the decree of God, <italic>Fiqh</italic> is accomplished <italic>via</italic> analysis by <italic>Ulama</italic> (clerics) of <italic>Al-Quran</italic> and <italic>Al-Hadith</italic>. <italic>Fiqh</italic> is neither sacred nor fixed, as it results from human opinion at a certain place and time and can be modified according to circumstances (<xref ref-type="bibr" rid="B3">3</xref>). When Muslims need clarity, <italic>Ulama</italic> perform <italic>ijtihad</italic> (best efforts) based on their understanding of <italic>Sharia</italic> and issue a <italic>Fatwa</italic> (ruling) to address questions. Since <italic>Fatwas</italic> are based on <italic>Fiqh</italic> and <italic>Ulama</italic>s&#x2019; <italic>ijtihad</italic>, varying scientific background and religious experience of <italic>Ulamas</italic> or authorized institutions may engender multiple different rulings on an issue, including vaccines (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>
<italic>Ulamas</italic> formulate <italic>Fatwas</italic> regarding COVID-19 vaccines by considering <italic>Sharia</italic> sources and scientific studies. During the <italic>Fatwa</italic> formulation process, <italic>Ulamas</italic> attempt to weigh religious and scientific values fairly (<xref ref-type="bibr" rid="B6">6</xref>). Fatwas are of critical importance to vaccine acceptance in Muslim populations, which have long had concerns about purity of contents (<xref ref-type="bibr" rid="B7">7</xref>). We herein describe current COVID-19 vaccine ingredients and how various authorized Islamic regulators have formed the relevant <italic>Fatwa</italic>s. Understanding vaccine regulation under Islamic law provides insights for increasing vaccine acceptance in Muslim-majority countries, especially during a pandemic.</p>
</sec>
<sec id="s2">
<title>Vaccine Ingredients</title>
<p>Vaccines can be generally classified as live or non-live, which distinguishes those containing attenuated replicating strains of the relevant pathogen from those containing only pathogen components or killed whole organisms. In addition to the &#x2018;traditional&#x2019; live and non-live vaccines, other platforms have been developed over the past few decades, including viral vectors and nucleic acid-based RNA vaccines (<xref ref-type="bibr" rid="B8">8</xref>). Several COVID-19 vaccines have been developed using these new technologies (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). Vaccines contain essential or active components that induce an immune response conferring protection upon subsequent exposure to the target pathogen. Apart from these active components, the main ingredient is typically water. Other ingredients may be added, including adjuvants to improve immunogenicity, preservatives, emulsifiers (such as polysorbate 80), or stabilizers (e.g., gelatin or sorbitol) (<xref ref-type="bibr" rid="B11">11</xref>). These added ingredients are typically present in very small quantities.</p>
<p>Products used during manufacturing could also theoretically remain in the final product and are included as potential trace vaccine components (<xref ref-type="bibr" rid="B8">8</xref>). For example, inactivation with formaldehyde is commonly used to produce human and animal vaccines such as those against polio, hepatitis A, enterovirus 71, and influenza viruses (<xref ref-type="bibr" rid="B12">12</xref>). The formaldehyde is diluted to trace levels in the final product and does not pose a safety concern (<xref ref-type="bibr" rid="B13">13</xref>). Other components may include antibiotics, egg or yeast proteins, latex, glutaraldehyde, and acidity regulators (such as potassium or sodium salts). Except in the case of allergy, such as yellow fever vaccination in the context of true egg allergy, there is no evidence of risk to human health from these trace components (<xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>COVID-19 vaccines use several different platforms, with varying active ingredients and excipients. Additionally, some approaches, such as mRNA-based vaccines, are synthetically created in a lab and therefore do not require cell culture during production (<xref ref-type="bibr" rid="B9">9</xref>). Composition of COVID-19 vaccines included in WHO&#x2019;s Emergency Use Listing (EUL) is described in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> (<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Active and excipient ingredients of COVID-19 vaccines included in WHO&#x2019;s Emergency Use Listing (EUL).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">COVID-19 Vaccine (developer)</th>
<th valign="top" align="center">Platform</th>
<th valign="top" align="center">Active Ingredients</th>
<th valign="top" align="center">Other Ingredients</th>
<th valign="top" align="center">Cell-line used for vaccine manufacture</th>
<th valign="top" align="center">Animal or human origin excipients in final product</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Sinovac-Coronavac</td>
<td valign="top" rowspan="2" align="left">Inactivated</td>
<td valign="top" rowspan="2" align="left">Each 0.5 mL dose is composed of 3 &#x3bc;g of &#x3b2;-propiolactone-inactivated SARS-CoV-2 virus (Wuhan/WIV04/2019 strain)</td>
<td valign="top" rowspan="2" align="left">Excipients are aluminium hydroxide adjuvant, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection. The vaccine does not contain preservatives.</td>
<td valign="top" rowspan="2" align="left">Vero cell, extracted from an African green monkey</td>
<td valign="top" rowspan="2" align="left">None</td>
</tr>
<tr>
<td valign="top" align="left">(Sinovac)</td>
</tr>
<tr>
<td valign="top" align="left">BIBP</td>
<td valign="top" rowspan="2" align="left">Inactivated</td>
<td valign="top" rowspan="2" align="left">Each 0.5 mL dose is composed of 6.5 U (4 &#x3bc;g) of &#x3b2;-propiolactone-inactivated SARS-CoV-2 antigens [19nCOV-CDC-TAN-HB02 strain (HB02 strain)]</td>
<td valign="top" rowspan="2" align="left">Excipients are aluminium hydroxide adjuvant and phosphate-buffered saline (PBS), which composed of disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate, and sodium chloride.</td>
<td valign="top" rowspan="2" align="left">Vero cell, extracted from an African green monkey</td>
<td valign="top" rowspan="2" align="left">None</td>
</tr>
<tr>
<td valign="top" align="left">(China National Biotec Group (CNBG), Sinopharm)</td>
</tr>
<tr>
<td valign="top" align="left">Vaxzevria or AstraZeneca/AZD1222 vaccine</td>
<td valign="top" rowspan="2" align="left">Viral Vector</td>
<td valign="top" rowspan="2" align="left">Each 0.5 mL dose contains 5 x 10<sup>10</sup> ChAdOx1-S (recombinant) viral particles, composed of a replication-deficient chimpanzee adenovirus vector encoding the S glycoprotein of SARS-CoV-2</td>
<td valign="top" rowspan="2" align="left">Excipients are L-histidine, L-histidine hydrochloride monohydrate, magnesium chloride hexahydrate, polysorbate 80, ethanol, sucrose, sodium chloride, disodium edetate dihydrate and water for injection.</td>
<td valign="top" rowspan="2" align="left">T-REx-293 cells, a derivative of the human embryonic kidney (HEK 293) cell line, descended from tissue taken from a 1973 abortion in the Netherlands from an undisclosed source.</td>
<td valign="top" rowspan="2" align="left">None</td>
</tr>
<tr>
<td valign="top" align="left">(Oxford University and AstraZeneca)</td>
</tr>
<tr>
<td valign="top" align="left">Janssen/Ad26.COV 2.S</td>
<td valign="top" rowspan="2" align="left">Viral Vector</td>
<td valign="top" rowspan="2" align="left">Each 0.5 ml dose contains 5 x 10<sup>10</sup> AD26.COV2.S viral particles, composed of replication-incompetent adenovirus type 26 (Ad26)-vectored monovalent vaccine encoding the SARS-CoV-2 spike (S) protein from the Wuhan-Hu-1 isolate (GenBank accession number MN908947), stabilized in its prefusion conformation</td>
<td valign="top" rowspan="2" align="left">Excipients are citric acid monohydrate, trisodium citrate dihydrate, ethanol, 2-hydroxypropyl-beta-cyclodextrin (HBCD), polysorbate 80, sodium chloride, sodium hydroxide, and hydrochloric acid. The vaccine does not contain preservatives.</td>
<td valign="top" rowspan="2" align="left">PER.C6G TetR cell line, derived from human embryonic retinal cells, obtained in 1985 from fetal retina tissue</td>
<td valign="top" rowspan="2" align="left">None</td>
</tr>
<tr>
<td valign="top" align="left">(Johnson &amp; Johnson)</td>
</tr>
<tr>
<td valign="top" align="left">Comirnaty or BNT162b2</td>
<td valign="top" rowspan="2" align="left">mRNA</td>
<td valign="top" rowspan="2" align="left">Each 30 mcg/0.3mL dose contains a highly purified single-stranded, 5`-capped mRNA, encoding a P2 mutant spike protein (PS 2) of SARS-CoV-2 virus.</td>
<td valign="top" rowspan="2" align="left">Excipients are ALC-0315, ALC-0159 (polyethylene glycol), cholesterol, potassium chloride, potassium dihydrogen phosphate, sodium chloride, disodium hydrogen phosphate dihydrate, sucrose, and water for injection.</td>
<td valign="top" rowspan="2" align="left">None (cell-free <italic>in vitro</italic> transcription process from DNA templates)</td>
<td valign="top" rowspan="2" align="left">None</td>
</tr>
<tr>
<td valign="top" align="left">(Pfizer&#x2013;BioNTech)</td>
</tr>
<tr>
<td valign="top" align="left">Spikevax or mRNA-1273 vaccine</td>
<td valign="top" rowspan="2" align="left">mRNA</td>
<td valign="top" rowspan="2" align="left">Each 100 mcg/0.5 mL dose contains a synthetic mRNA (single-stranded, 5&#x2019;-capped) encoding the prefusion-stabilized spike glycoprotein (S) of SARS-CoV-2 virus.</td>
<td valign="top" rowspan="2" align="left">Excipients are lipids [SM-102, 1,2-dimyristoyl-rac-glycero-3- methoxypolyethylene glycol-2000 (PEG2000-DMG), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)], tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose.</td>
<td valign="top" rowspan="2" align="left">None (cell-free <italic>in vitro</italic> transcription process from DNA templates)</td>
<td valign="top" rowspan="2" align="left">None</td>
</tr>
<tr>
<td valign="top" align="left">(Moderna)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3">
<title>
<italic>Halal</italic> Aspect of Vaccines</title>
<p>Vaccination coverage varies with access, affordability, awareness, and acceptance. Vaccine acceptance is a crucial component of disease prevention, as vaccines are only effective if used. However, some Muslim individuals have concerns that vaccines and other pharmaceuticals may not be <italic>Halal</italic>, and are therefore more likely to remain unvaccinated (<xref ref-type="bibr" rid="B20">20</xref>). There is also heterogeneity in the influence of religion on vaccination practices amongst Muslim-majority countries. In Saudi Arabia, an Islamic theocracy, a survey showed that parents were highly confident in vaccines; even vaccine-hesitant parents did not view religion as prohibiting vaccination. Conversely in Pakistan, which has the world&#x2019;s second-largest Muslim population after Indonesia, local rumours with religious undertones falsely asserted that the polio vaccine causes sterilization and contains porcine products. Pakistan continues to see polio outbreaks (<xref ref-type="bibr" rid="B21">21</xref>).</p>
<p>
<italic>Halal</italic> products are those which are permitted according to the <italic>Sharia</italic> law. Typically, <italic>Halal</italic> refers to the permissibility to eat, drink, or act based on Islamic law and principles. Substances used in vaccine manufacturing may be of animal origin, including swine or derivatives, dead animals, or blood, which are <italic>Haram</italic> or forbidden for Muslims to consume (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B22">22</xref>). In Islam, Muslims are required to follow <italic>Sharia</italic> law, which is authoritative. The Holy <italic>Al-Quran</italic> states: &#x201c;<italic>Therefore, (O Believers) eat of the lawful and good things that Allah has provided for you, and be grateful for His favours if it is true that you only worship Him. Indeed, Allah has forbidden you that which dies of itself, blood, and the flesh of swine; also, any flesh consecrated to something other than in the name of Allah. But whoever is compelled by necessity (to eat any of this) not intending to sin or transgress (regarding the quantity eaten), will find Allah Most Forgiving, Most Merciful</italic>&#x201d;. (Q.S. An-Nahl 16:114-115). The passage explains why Muslims abstain from using <italic>Haram</italic> material or consuming porcine products and derivatives (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B23">23</xref>).</p>
<p>Swine are amongst the animals declared as <italic>Haram</italic> by <italic>Sharia</italic> law. Using their parts and derivatives in pharmaceuticals will render them non-permissible for consumption by Muslims (<xref ref-type="bibr" rid="B22">22</xref>). However, swine derivatives are commonly used in vaccine production, including porcine trypsin and porcine gelatine. Porcine trypsin extracted from the swine pancreas is a reagent used during the propagation stage of production of certain vaccines, e.g., inactivated polio and Japanese encephalitis virus vaccines, to remove or detach cells from the culture tank or vessels before harvesting. It may also be used during the final culture stage of virus production for vaccine activation, such as with influenza virus and rotavirus. Although semi-synthetic (recombinant) trypsin is commercially available, porcine trypsin is commonly used for its lower cost and availability. Porcine trypsin is washed from harvested cells before further processing. Its presence is typically assessed by validated techniques, studies of which have mostly demonstrated undetectable amounts of porcine trypsin in final products (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B24">24</xref>).</p>
<p>Hydrolyzed porcine gelatine is a mixture of peptides and proteins produced by partial hydrolysis of collagen, typically extracted from swine skin, tendons, ligaments, bones, cartilage, or other components. Porcine gelatine is used in vaccines to stabilize and preserve active ingredients during freeze-drying and storage. Unlike food grade gelatine, the gelatine used for vaccine production is highly purified and broken down into peptides. Although only present in small amounts, a label stating &#x201c;Contains trace quantities of porcine content&#x201d; is sometimes required by local product registration policy (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B24">24</xref>).</p>
</sec>
<sec id="s4">
<title>
<italic>Fatwa</italic> Formulation for Covid-19 Vaccines</title>
<p>In Muslim-populated countries, <italic>Halal</italic> certification administrators use the Holy <italic>Al-Quran</italic> as a guide for granting the <italic>Halal</italic> certificate to applicants. Administrators evaluate the cleanliness of the applicant&#x2019;s premises and equipment, selection of ingredients, and cross-contamination between <italic>Halal</italic> and <italic>non-Halal</italic> products (<xref ref-type="bibr" rid="B25">25</xref>). &#x201c;<italic>Halal</italic> pharmaceuticals&#x201d; must contain only ingredients permitted by <italic>Sharia</italic> law. They must specifically: (1) be free of parts or derivatives of animals declared non-Halal by <italic>Sharia</italic> law or not slaughtered according to <italic>Sharia</italic> law; (2) not contain <italic>najs</italic> (impurities); and (3) not be poisonous, intoxicating, or pose a health hazard to users when taken according to prescription (<xref ref-type="bibr" rid="B22">22</xref>). However, interpretation and implementation of <italic>Halal</italic> pharmaceutical certification varies between countries.</p>
<p>Indonesia has the world&#x2019;s largest Muslim population, with 87% of its 277 million inhabitants identifying as Muslim. It is diverse in terms of language, ethnicity, and cultural background which, in addition to religion, impact vaccine perception. A <italic>fatwa</italic>, or ruling under Islamic law, to declare <italic>Halal</italic> status of a vaccine can be issued by Indonesia&#x2019;s authorized <italic>Halal</italic> certification administrators, Indonesian Ulama Council (MUI) (<xref ref-type="bibr" rid="B21">21</xref>). The first COVID-19 vaccine authorized in the country, Sinovac, was granted a <italic>Halal</italic> and holy certificate by the MUI on January 11, 2021. The certification states that this vaccine does not use porcine trypsin or other animal enzymes during manufacturing (<xref ref-type="bibr" rid="B26">26</xref>). The MUI subsequently issued a fatwa on March 19, 2021 stating that the AstraZeneca COVID-19 vaccine is &#x201c;<italic>Haram-permittable</italic>&#x201d;. MUI claimed it is <italic>Haram</italic> because it uses porcine trypsin during the early production process, but is <italic>permittable</italic> to use (or <italic>Mubah</italic>) due to the urgency of addressing COVID-19 (<xref ref-type="bibr" rid="B27">27</xref>). Notably, several other nations with Muslim majority populations, including Saudi Arabia, the United Arab Emirates, Egypt, and Malaysia, use AstraZeneca vaccine without concern over whether it is <italic>Halal</italic> or <italic>Haram</italic> (<xref ref-type="bibr" rid="B28">28</xref>). Additionally, the Indonesian Food and Drug Monitoring Agency (BPOM) and WHO have confirmed the absence of porcine products in the AstraZeneca vaccine (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B28">28</xref>). Some COVID-19 vaccines, the Sinopharm and Pfizer-BioNTech vaccines are also deemed <italic>Haram-permittable</italic>, and can be used for emergencies. Other COVID-19 vaccines that have been granted EUA from BPOM, such as Moderna, J&amp;J, Sputnik V, and CanSino, are not yet <italic>Halal/Haram</italic> certified by MUI as of September 2021 (<uri xlink:href="https://mui.or.id/">https://mui.or.id/</uri>).</p>
<p>Some fear that COVID-19 vaccines will suffer the same fate as the measles&#x2212;rubella combination vaccine introduced to Indonesia in 2017 (<xref ref-type="bibr" rid="B28">28</xref>). At that time, MUI issued a <italic>fatwa</italic> that the vaccine was <italic>Haram</italic> due to porcine components being used in the manufacturing process. After the MUI <italic>fatwa</italic> declaring it <italic>Haram</italic>, uptake declined precipitously. While all six provinces on Java reached the 95% coverage target and saw measles and rubella cases decline by over 90%, coverage of children on other islands has reached only 68%. In Aceh, the only province allowed to practice <italic>Sharia</italic> law, coverage is only 8%, putting Indonesia at risk for a measles outbreak (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B29">29</xref>). COVID-19 vaccine coverage disparities are also seen amongst provinces. Aceh again demonstrates extremely low coverage, with only 11.8% of its target population being fully vaccinated (<uri xlink:href="https://vaksin.kemkes.go.id/">https://vaksin.kemkes.go.id/</uri>). Religious considerations should be addressed in vaccine roll-out, with the engagement of religious leaders as a priority, since the <italic>fatwa</italic> specifically permits the use of non-<italic>Halal</italic> vaccines in the emergency (<xref ref-type="bibr" rid="B21">21</xref>).</p>
</sec>
<sec id="s5">
<title>Reconciling <italic>Sharia</italic> Law With Contemporary Needs</title>
<p>Despite potential conflict with <italic>Sharia</italic> law, clerics in several Muslim countries have accepted vaccines that utilize impure substances such as porcine gelatine in their production process. They concluded that gelatine in vaccines is <italic>Halal</italic> because it has undergone hydrolysis, which purifies it under an Islamic legal concept called <italic>istihalah</italic> (perfect change) (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B30">30</xref>). <italic>Istihalah</italic> refers to alteration of physicochemical nature to change a non-acceptable <italic>Haram</italic> product to an acceptable <italic>Halal</italic> form (<xref ref-type="bibr" rid="B31">31</xref>). This view is based on the principle of &#x201c;transformation&#x201d; in <italic>Sharia</italic> law, which is applied to vinegar production from wine (<xref ref-type="bibr" rid="B2">2</xref>). Vaccines become acceptable if the impure component is completely transformed into a new substance, different from its origin. Transformation of impure substances through downstream processing, e.g. filtration, to render them negligible in the final product is similarly used with other pharmaceuticals such as Heparin (porcine enzymes) and the Rotavirus vaccine (porcine trypsin). In Muslim jurisprudence, these processes accomplish <italic>istihalah</italic> and render the final product permissible for Muslim use (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>).</p>
<p>In addition to <italic>istihalah</italic>, <italic>istihlak</italic> (mixing) can convert an unclean substance into one that is clean (<xref ref-type="bibr" rid="B34">34</xref>). <italic>&#x2018;Istihlak&#x2019;</italic> refers to mixing of a substance with another until it is dissolved, causing loss of properties even though the substance still exists. Thus an unclean product can be mixed with a more dominant clean product to vanquish the unclean characteristics. This concept is adapted from the <italic>Hadith</italic>, which explains the characteristic of two <italic>kolah</italic> (about 216-270 litres) of water: &#x201c;<italic>The Prophet was asked about the status of stagnant water being licked by reptiles and wild animals (i.e., whether the water is still clean). Then the Prophet said, &#x201c;If the water exceeds two kolah, then it does not become unclean&#x201d;</italic>. Another hadith explains &#x201c;<italic>If the water exceeds two kolah, and is then mixed with the unclean, it does not become unclean as long as there is no change in its smell and taste</italic>&#x201d; (<xref ref-type="bibr" rid="B33">33</xref>).</p>
<p>The concepts of <italic>istihalah</italic> and <italic>istihlak</italic> are not universally accepted by all <italic>Ulamas</italic> and authorization councils which determine <italic>Halal</italic> status. Acceptance by <italic>fatwa</italic> institutions varies based upon interpretation of Sharia law (<xref ref-type="bibr" rid="B33">33</xref>). However, during the COVID-19 pandemic, all councils agreed that an effective and safe COVID vaccine is a basic necessity, or <italic>darurat</italic> (emergency). Recognition as <italic>darurat</italic> justifies consumption of <italic>Haram</italic> product if needed in an emergency situation (<xref ref-type="bibr" rid="B35">35</xref>). The Holy <italic>al-Quran</italic> states: &#x201c;<italic>He has only forbidden you what dies of itself (carrion) and blood and the flesh of swine, and that which is slaughtered as a sacrifice for others than Allah. But if one is forced by necessity without willful disobedience nor transgressing due limits, then there is no sin on them. Truly, Allah is Oft-Forgiving, Most Merciful</italic>&#x201d; (Q.S. Al-Baqarah 2:173). COVID-19 vaccines are recognized as necessary or critical for saving lives and ensuring that societies can function. They are equivalent in status to other established basic human needs such as food and shelter, and therefore are eligible to be classified as <italic>darurat</italic>. A vaccine that protects against harm from SARS-CoV-2 is essential to uphold the principles of sanctity of human life and avoidance of harm (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>The COVID-19 vaccine development process is also consistent with the principle of the avoidance of harm in Islamic jurisprudence. All vaccines approved for public use undergo stringent safety and efficacy evaluation, which conform to requirements of national ethics bodies (<xref ref-type="bibr" rid="B36">36</xref>). Vaccine development reflects the <italic>Qur&#x2019;an&#x2019;</italic>s concept of prevention, or <italic>wiqaya</italic>, which can refer to preventive actions such as against hell-fire, punishment, greed, bad acts, harm and heat. The <italic>Qur&#x2019;an</italic> concludes that prevention is one of the laws of God, so it also applies to the role of vaccination for preventing harm to humans (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B37">37</xref>). This consideration in combination with scientific data provided a basis for <italic>fatwa</italic> councils worldwide to publish Islamic legal rulings permitting use of recently developed COVID-19 vaccines, listed in <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>
<italic>Fatwa</italic> (Ruling) status and considerations for granting <italic>Halal</italic> certification of COVID-19 vaccines in several countries.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">
<italic>Halal</italic> certification administrators</th>
<th valign="top" align="center">Considerations for <italic>Halal</italic> Certification for COVID-19 Vaccines</th>
<th valign="top" align="center">Conclusion Fatwa (Islamic Ruling)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" rowspan="3" align="left">Ulama Council of Indonesia (MUI) (<uri xlink:href="http://www.mui.or.id">www.mui.or.id</uri>)</td>
<td valign="top" align="left">Vaccines are required to use <italic>Halal</italic> (permissible) and holy (clean) ingredients. In granting the fatwa for vaccines, three principles must be met:</td>
<td valign="top" align="left">
<list list-type="order">
<list-item>
<p>Sinovac-Coronavac is deemed &#x201c;holy and <italic>Hala</italic>l&#x201d;</p>
</list-item>
<list-item>
<p>AstraZeneca, Sinopharm and Pfizer-BioNTech vaccine are deemed <italic>Haram</italic> since they use porcine trypsin during manufacturing or contain animal products. Vaccination is permissible by Islamic laws because there is an urgent need to vaccinate immediately and sufficient clean and <italic>Halal</italic> product is not available</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td valign="top" align="left">
<list list-type="order">
<list-item>
<p>Raw materials, additives, and auxiliary materials must be <italic>Halal</italic>
</p>
</list-item>
<list-item>
<p>The manufacturing process must be guaranteed not to be contaminated with impurities (<italic>najs</italic>)</p>
</list-item>
<list-item>
<p>The manufacturer has a system to guarantee <italic>Halal</italic> processes throughout production.</p>
</list-item>
</list>However, immunization with non-<italic>Halal</italic> vaccines may be allowed under certain conditions:</td>
<td valign="top" align="left">Note:</td>
</tr>
<tr>
<td valign="top" align="left">
<list list-type="order">
<list-item>
<p>When used in an emergency condition, known as <italic>al- hajat</italic>, or</p>
</list-item>
<list-item>
<p>
<italic>Halal</italic> and holy vaccine ingredients have not been found and there is information from competent and trusted medical personnel that no <italic>Halal</italic> vaccine is available.</p>
</list-item>
<list-item>
<p>If non-immunization will cause death, serious illness, or permanent life-threatening disability, then legal immunization is mandatory.</p>
</list-item>
</list>
</td>
<td valign="top" align="left">This fatwa is questionable since MUI&#x2019;s claim that trypsin of a porcine origin was used in the manufacturing process differs from the vaccines manufacturers&#x2019; statement that declares NO animal or human origin excipients present in their final products.</td>
</tr>
<tr>
<td valign="top" align="left">Fatwa Council of the United Arab Emirates (<uri xlink:href="http://www.awqaf.gov.ae">www.awqaf.gov.ae</uri>)</td>
<td valign="top" align="left">
<list list-type="order">
<list-item>
<p>COVID-19 is a highly contagious disease that could cause death or permanent damage to humans. The vaccine is the only way to protect against this virus.</p>
</list-item>
<list-item>
<p>COVID-19 vaccines are in compliance with Sharia (Islamic law) objectives to protect the human body and with other relevant Islamic rulings.</p>
</list-item>
<list-item>
<p>Even though the vaccine might contain non-<italic>Halal</italic> ingredients, it is acceptable to use it when there are no alternatives.</p>
</list-item>
<list-item>
<p>Vaccines are categorized as preventive medicines that help society avoid the high risk of infection.</p>
</list-item>
</list>
</td>
<td valign="top" align="left">COVID-19 vaccines are <italic>Halal</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">Fiqh Academy of the Organization of Islamic Cooperation, Saudi Arabia (<uri xlink:href="http://www.iifa-aifi.org">www.iifa-aifi.org</uri>)</td>
<td valign="top" align="left">
<list list-type="order">
<list-item>
<p>Specialists in pharmacology and preventive medicine confirm that the COVID-19 vaccines consist of the messenger RNA (ribonucleic acid) of SARS-CoV-2, recombinant DNA, the common cold virus (adenovirus), other viruses, bacteria, compounds of the Quillaja tree and plants, and auxiliary substances such as potassium, sodium, magnesium, phosphate, acetic acid, tromethamine hydrochloride, diacetate, polysorbate, sucrose, lipids, cholesterol, histidine, ethanol and water. These vaccines do not contain swine or human derivatives</p>
</list-item>
<list-item>
<p>During production, chemical reactions and transformations occur, which fall within the <italic>Sharia</italic> rulings regarding metamorphosis in Islamic jurisprudence (<italic>istihalah</italic>).</p>
</list-item>
<list-item>
<p>Vaccination becomes mandatory if the government obligates it, because the government&#x2019;s rulings uphold public interests</p>
</list-item>
</list>
</td>
<td valign="top" align="left">COVID-19 Vaccines are permissible according to Sharia law (<italic>Halal</italic>).</td>
</tr>
<tr>
<td valign="top" align="left">Islamic Religious Council of Singapore (<uri xlink:href="http://www.muis.gov.sg">www.muis.gov.sg</uri>)</td>
<td valign="top" align="left">
<list list-type="order">
<list-item>
<p>Vaccines are a basic necessity</p>
</list-item>
<list-item>
<p>Vaccines are safe and efficacious</p>
</list-item>
<list-item>
<p>Ingredients used in vaccines are permissible.</p>
</list-item>
</list>
</td>
<td valign="top" align="left">Thus far, COVID-19 vaccines (Pfizer-BioNTech and Moderna) in the national program do not diverge from <italic>Sharia</italic> considerations. As such, we hold the position that a COVID-19 vaccine is permissible for Muslim use (<italic>Halal</italic>).</td>
</tr>
<tr>
<td valign="top" align="left">Taiwan <italic>Halal</italic> Certification Bodies (Chinese Muslim Association and Taipei Grand Mosque) (<uri xlink:href="http://www.cdc.gov.tw">www.cdc.gov.tw</uri>)</td>
<td valign="top" align="left">
<list list-type="order">
<list-item>
<p>None of the COVID-19 vaccines granted Emergency Use Authorization (EUA) in Taiwan, including the vaccines from AstraZeneca, Moderna, Pfizer-BioNTech and Medigen, contain swine cells</p>
</list-item>
<list-item>
<p>Many large fatwa councils around the world have already published Islamic legal rulings regarding the permissibility of the recently developed COVID-19 vaccines.</p>
</list-item>
</list>
</td>
<td valign="top" align="left">COVID-19 vaccines are <italic>Halal</italic> as they do not contain animal products of any kind.</td>
</tr>
<tr>
<td valign="top" align="left">The Islamic Food and Nutrition Council of America (IFANCA) or Assembly of Muslim Jourist of America (AMJA) (<uri xlink:href="http://www.amjaonline.org">www.amjaonline.org</uri>)</td>
<td valign="top" align="left">
<list list-type="order">
<list-item>
<p>Vaccine approval is not a decision made by one person or company, but by the Food and Drug Administration (FDA) and similar agencies in other countries which follow stringent practices that consider the risk-benefit ratio, congruent with the principles of Sharia</p>
</list-item>
<list-item>
<p>As for the possibility of cultivating some viruses in porcine cells (if actually taking place), the vaccine would usually contain none of the cellular parts. This makes the <italic>najasah</italic> (impurity) occur only by proximity (<italic>mujawarah</italic>). In addition to being microscopic, trivial things of this nature should be excused, particularly when the matter pertains to protecting people from this disastrous pandemic.</p>
</list-item>
<list-item>
<p>Medical experts in virology and vaccines who are involved in COVID-19 research have clearly stated that the benefits of COVID-19 vaccinations far outweigh their risks.</p>
</list-item>
</list>
</td>
<td valign="top" align="left">All the vaccines approved in the US (Pfizer-BioNTech, Moderna, J&amp;J) have been deemed permissible to use (<italic>Halal</italic>).</td>
</tr>
<tr>
<td valign="top" align="left">Wifaqul Ulama (Britain) (<uri xlink:href="http://www.wifaqululama.co.uk">www.wifaqululama.co.uk</uri>)</td>
<td valign="top" align="left">
<list list-type="simple">
<list-item>
<p>1.&#x2003;Considerations for the AstraZeneca Vaccine:</p>
</list-item>
<list-item> <p>a. Ethanol content is very small (0.002 g of alcohol/ethanol per dose of 0.5 mL). This is not enough to cause any noticeable effects.</p>
</list-item>
<list-item> <p>b. Vaccine production uses the HEK 293 TREX producer cell line originally derived from kidney cells from a female foetus aborted in the 1970s. None of the original foetus derived cells are used in the vaccine and purification was performed by CsCl gradient ultracentrifugation to remove the cell culture material.</p>
</list-item>
<list-item>
<p>2.&#x2003;Considerations for the Pfizer-BioNTech Vaccine:</p>
</list-item>
<list-item> <p>a. The main ingredient in this vaccine is nucleoside-modified messenger RNA and it is not sourced from animals</p>
</list-item>
<list-item> <p>b. All excipients apart from cholesterol are chemically synthesised. The following official statement was released: &#x201c;The Medicines and Healthcare products Agency confirms that the Pfizer/BioNTech COVID-19 vaccine does not contain any components of animal origin.&#x201d;</p>
</list-item>
<list-item>
<p>3.&#x2003;Considerations for the Moderna Vaccine:</p>
</list-item>
<list-item> <p>a. The following official statement was released, &#x201c;The Medicines and Healthcare products Agency can confirm that the Moderna COVID-19 vaccine does not contain any components of animal origin.&#x201d;</p>
</list-item>
</list>
</td>
<td valign="top" align="left">In the light of the available data, official statement and clarification, Wifaqul Ulama concluded that COVID-19 vaccines (AstraZeneca, Pfizer, and Moderna) are permissible for British Muslims (<italic>Halal</italic>).</td>
</tr>
<tr>
<td valign="top" align="left">Australian Fatwa Council (<uri xlink:href="http://www.anic.org.au">www.anic.org.au</uri>)</td>
<td valign="top" align="left">
<list list-type="simple">
<list-item>
<p>1.&#x2003;COVID-19 Vaccines are safe</p>
</list-item>
<list-item>
<p>2.&#x2003;In the final vaccine product, there are no gelatine, animal products or cells of any kind remaining</p>
</list-item>
<list-item>
<p>3.&#x2003;None of the vaccine types appears to affect the DNA inside our cells, nor have any vaccines (which have been used for decades) been shown to affect human DNA</p>
</list-item>
<list-item>
<p>4.&#x2003;Medical experts in virology and vaccines who are involved in COVID-19 research have clearly stated that the benefits of these vaccinations far outweigh their risks.</p>
</list-item>
</list>
</td>
<td valign="top" align="left">The COVID-19 Vaccines (Pfizer-BioNTech, Moderna, AstraZeneca) are permissible according to Islamic law as there is no known religious harm attributed to being vaccinated nor does it contain any forbidden substances (<italic>Halal</italic>).</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Vaccines are required to be manufactured under current good manufacturing practices (cGMP) (<xref ref-type="bibr" rid="B38">38</xref>&#x2013;<xref ref-type="bibr" rid="B40">40</xref>). cGMP requires that products for human administration should not be contaminated with extraneous materials, including those of animal origin (9 C.F.R. &#xa7; 113 and 21 C.F.R. 610) (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). Regulations addressing cell culture based biologics became particularly important after the discovery that variant Creutzfeldt-Jakob disease (vCJD) could be transmitted between species by &#x201c;prions&#x201d; or infectious protein, without involving any nucleic acids (<xref ref-type="bibr" rid="B43">43</xref>). There is a current push to utilize animal-component-free (ACF) or xeno-free reagents (<xref ref-type="bibr" rid="B44">44</xref>).  In recent years, progress has been made to generate serum-free media alternatives and ACF products for pharmaceutical manufacturing, including vaccine production. As growth media influences cells&#x2019; characteristics, safety and efficacy, comparative studies are essential to understanding the differences, advantages, and challenges associated with specific serum-free/ACF formulations. Nevertheless, the use of ACF reagents during vaccine manufacturing aligns with the <italic>Halal</italic> way in <italic>Sharia</italic>, without depending on the acceptance of <italic> Istihalah </italic> and <italic> Istihlak </italic> concepts. Thus, the broader use of ACF products in vaccine manufacturing, especially in Muslim countries, could ameliorate vaccine hesitancy associated with Muslim religious beliefs.</p>
</sec>
<sec id="s6" sec-type="conclusions">
<title>Conclusions</title>
<p>From the Islamic point of view, preserving life is aligned with preserving religion (<xref ref-type="bibr" rid="B35">35</xref>). Muslims who refuse to receive COVID-19 vaccines may be regarded as acting against <italic>Sharia</italic> law. Yet <italic>Halal</italic> certification is only one of many issues that may affect vaccine uptake. The anti-vaccination movement, concerns about long term side effects, accessibility and mis-information pose additional challenges. Effective scientific discourse and communication, including regular engagement with Islamic law scholars, <italic>Ulamas</italic>, and national regulatory agencies, will be critical for achieving vaccination targets (<xref ref-type="bibr" rid="B45">45</xref>).</p>
<p>Individual decisions about accepting COVID-19 vaccines are multifactorial. The <italic>Halal</italic> issue may pose a significant challenge amongst Muslim populations. <italic>Fatwa</italic> councils worldwide have used both <italic>sharia</italic> and scientific approaches to grant <italic>Halal</italic> certificates for COVID-19 vaccines. Yet there have been inconsistencies across regions. For example, the AstraZeneca COVID-19 vaccine is considered <italic>Haram</italic> by the Indonesian council but <italic>Halal</italic> by other councils. Nonetheless, all <italic>fatwa</italic> councils agree that vaccines are necessary in the context of our current pandemic, and thus receiving a COVID-19 vaccination is actually a form of compliance with <italic>Sharia</italic> law. Broader use of ACF reagents during manufacturing may further increase acceptance among Muslims.</p>
</sec>
<sec sec-type="data-availability" id="s7">
<title>Data Availability Statement</title>
<p>The datasets presented in this article are not readily available because the study did not analyze any particular data, we reviewed published articles and Islamic laws. Requests to access the datasets should be directed to <email xlink:href="mailto:ymardian@ina-respond.net">ymardian@ina-respond.net</email>.</p>
</sec>
<sec sec-type="author-contributions" id="s8">
<title>Author Contributions</title>
<p>YM and C-YL conceptualized the manuscript. YM drafted the manuscript. YM, KS-S, and C-YL reviewed the draft of the manuscript, literature, provided critical insights, edited and prepared the final version of the manuscript. All authors analysed, reviewed, and edited the manuscript&#x2019;s final version and approved it for publication.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>This work has been funded in whole or in part with MOH Indonesia; the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Institutes of Health; and Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract Nos. HHSN261200800001E and HHSN261201500003I. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.</p>
</sec>
<sec id="s10">
<title>Author Disclaimer</title>
<p>The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.</p>
</sec>
<sec sec-type="COI-statement" id="s11">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We are grateful to Adhella Menur Naysilla for her feedback and in-depth religious insight. We also thank the Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) Network for the operational support and technical assistance.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ball</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>The Lightning-Fast Quest for COVID Vaccines - and What It Means for Other Diseases</article-title>. <source>Nature</source> (<year>2021</year>) <volume>589</volume>(<issue>7840</issue>):<page-range>16&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/d41586-020-03626-1</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grabenstein</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>What the World&#x2019;s Religions Teach, Applied to Vaccines and Immune Globulins</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>(<issue>16</issue>):<page-range>2011&#x2013;23</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.02.026</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yusroh</surname> <given-names>Y</given-names>
</name> <name>
<surname>Rahman</surname> <given-names>MZA</given-names>
</name>
</person-group>. <article-title>Mapping Contemporary Islamic Jurisprudence of Mu&#x1E25;ammad Sa&#x2bb;&#x12b;d Al-&#x2019;Ashm&#x101;w&#x12b; and Mu&#x1E25;ammad Sha&#x1E25;r&#x16b;r</article-title>. <source>IJISH (Int J Islamic Stud Humanit)</source> (<year>2018</year>) <volume>1</volume>(<issue>1</issue>):<fpage>32</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.26555/ijish.v1i1.132</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thalib</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Distinction of Characteristics Sharia and Fiqh on Islamic Law</article-title>. <source>Yuridika</source> (<year>2018</year>) <volume>33</volume>(<issue>3</issue>):<page-range>439&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.20473/ydk.v33i3.9459</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khoiri</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>The Mapping of Renewal of &#x2018;Usul Fiqh&#x2019;thoughts in Indonesia</article-title>. <source>Int J Language Res Educ Stud</source> (<year>2017</year>) <volume>1</volume>(<issue>1</issue>):<fpage>18</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.30575/2017081202</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ab Latiff</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zakaria</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>The Challenges in Implementation of Halal Vaccine Certification in Malaysia</article-title>. <source>J Food Pharm Sci</source> (<year>2021</year>) <volume>9</volume>(<issue>1</issue>):<fpage>2</fpage>. doi: <pub-id pub-id-type="doi">10.22146/jfps.1147</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname> <given-names>LP</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>PF</given-names>
</name>
<name>
<surname>AbuBakar</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Vaccine Hesitancy and the Resurgence of Vaccine Preventable Diseases: The Way Forward for Malaysia, a Southeast Asian Country</article-title>. <source>Hum Vaccines Immunother</source> (<year>2020</year>) <volume>16</volume>(<issue>7</issue>):<page-range>1511&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21645515.2019.1706935</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollard</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Bijker</surname> <given-names>EM</given-names>
</name>
</person-group>. <article-title>A Guide to Vaccinology: From Basic Principles to New Developments</article-title>. <source>Nat Rev Immunol</source> (<year>2021</year>) <volume>21</volume>(<issue>2</issue>):<fpage>83</fpage>&#x2013;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41577-020-00479-7</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathew</surname> <given-names>S</given-names>
</name>
<name>
<surname>Faheem</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hassain</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Benslimane</surname> <given-names>FM</given-names>
</name>
<name>
<surname>Thani</surname> <given-names>AAA</given-names>
</name>
<name>
<surname>Zaraket</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Platforms Exploited for SARS-Cov-2 Vaccine Development</article-title>. <source>Vaccines (Basel)</source> (<year>2020</year>) <volume>9</volume>(<issue>1</issue>):<fpage>11</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines9010011</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tenchov</surname> <given-names>R</given-names>
</name>
<name>
<surname>Smoot</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Watkins</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Q</given-names>
</name>
</person-group>. <article-title>A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development</article-title>. <source>ACS Cent Sci </source> (<year>2021</year>) <volume>7</volume>(<issue>4</issue>):<page-range>512&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acscentsci.1c00120</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kocourkova</surname> <given-names>A</given-names>
</name>
<name>
<surname>Honegr</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kuca</surname> <given-names>K</given-names>
</name>
<name>
<surname>Danova</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Vaccine Ingredients: Components That Influence Vaccine Efficacy</article-title>. <source>Mini Rev Med Chem</source> (<year>2017</year>) <volume>17</volume>(<issue>5</issue>):<page-range>451&#x2013;66</page-range>. doi: <pub-id pub-id-type="doi">10.2174/1389557516666160801103303</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilton</surname> <given-names>T</given-names>
</name>
<name>
<surname>Dunn</surname> <given-names>G</given-names>
</name>
<name>
<surname>Eastwood</surname> <given-names>D</given-names>
</name>
<name>
<surname>Minor</surname> <given-names>PD</given-names>
</name>
<name>
<surname>Martin</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Effect of Formaldehyde Inactivation on Poliovirus</article-title>. <source>J Virol</source> (<year>2014</year>) <volume>88</volume>(<issue>20</issue>):<page-range>11955&#x2013;64</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.01809-14</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>U. S. Food and Drug Administration</collab>
</person-group>. <source>Common Ingredients in US Licensed Vaccines</source> (<year>2014</year>). Available at: <uri xlink:href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-us-licensed-vaccines">https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-us-licensed-vaccines</uri>.</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>. <source>Background Document on the Inactivated Vaccine Sinovac-Coronavac Against COVID-19</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>2021</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1">https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1</uri>.</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>. <source>Background Document on the Inactivated COVID-19 Vaccine BIBP Developed by China National Biotec Group (CNBG)</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization Rome, Italy</publisher-name> (<year>2021</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BIBP-background-2021.1">https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BIBP-background-2021.1</uri>.</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>. <source>Background Document on the AZD1222 Vaccine Against COVID-19 Developed by Oxford University and Astrazeneca: Background Document to the WHO Interim Recommendations for Use of the AZD1222 (Chadox1-s [Recombinant]) Vaccine Against COVID19 Developed by Oxford</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>2021</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/background-document-on-the-azd1222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazeneca">https://www.who.int/publications/i/item/background-document-on-the-azd1222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazeneca</uri>.</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>. <source>Interim Recommendations for the Use of the&#xa0;Janssen Ad26. COV2. s (COVID-19) Vaccine. Background Document on the Janssen Ad26COV2S (COVID-19) Vaccine: Background Document to the WHO Interim Recommendations for Use of Ad26COV2S (COVID-19) Vaccine</source> (<year>2021</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad26.COV2.S-background-2021.1">https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad26.COV2.S-background-2021.1</uri>.</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>. <source>Background Document on Mrna Vaccine BNT162b2 (Pfizer-Biontech) Against COVID-19. License: CC by-NC-SA 3.0 IGO</source> (<year>2021</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19">https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19</uri>.</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>. <source>Background Document on the Mrna-1273 Vaccine (Moderna) Against COVID-19: Background Document to the WHO Interim Recommendations for Use of the Mrna-1273 Vaccine (Moderna)</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>2021</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/background-document-on-the-mrna-1273-vaccine-(moderna)-against-covid-19">https://www.who.int/publications/i/item/background-document-on-the-mrna-1273-vaccine-(moderna)-against-covid-19</uri>.</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kabir</surname> <given-names>R</given-names>
</name>
<name>
<surname>Mahmud</surname> <given-names>I</given-names>
</name>
<name>
<surname>Chowdhury</surname> <given-names>MTH</given-names>
</name>
<name>
<surname>Vinnakota</surname> <given-names>D</given-names>
</name>
<name>
<surname>Jahan</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Siddika</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>COVID-19 Vaccination Intent and Willingness to Pay in Bangladesh: A Cross-Sectional Study</article-title>. <source>Vaccines (Basel)</source> (<year>2021</year>) <volume>9</volume>(<issue>5</issue>):<fpage>416</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines9050416</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harapan</surname> <given-names>H</given-names>
</name>
<name>
<surname>Shields</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kachoria</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Shotwell</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wagner</surname> <given-names>AL</given-names>
</name>
</person-group>. <article-title>Religion and Measles Vaccination in Indonesia, 1991-2017</article-title>. <source>Am J Prev Med </source> (<year>2021</year>) <volume>60</volume>(<supplement>1 Suppl 1</supplement>):<page-range>S44&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.amepre.2020.07.029</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khoo</surname> <given-names>YSK</given-names>
</name>
<name>
<surname>Ghani</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Navamukundan</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Jahis</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gamil</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Unique Product Quality Considerations in Vaccine Development, Registration and New Program Implementation in Malaysia</article-title>. <source>Hum Vaccines Immunother</source> (<year>2020</year>) <volume>16</volume>(<issue>3</issue>):<page-range>530&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1080/21645515.2019.1667206</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Al-Teinaz</surname> <given-names>YR</given-names>
</name>
</person-group>. <article-title>What is Halal Food</article-title>? In: <source>The Halal Food Handbook</source> (<year>2020</year>). <publisher-loc>Hoboken, New Jersey</publisher-loc>: <publisher-name>Wiley Online Library</publisher-name>. p. <fpage>7</fpage>&#x2013;<lpage>26</lpage>.</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Agency EM</collab>
</person-group>. <source>Guideline on the Use of Porcine Trypsin Used in the Manufacture of Human Biological Medicinal Products</source> (<year>2013</year>). Available at: <uri xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500139532.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500139532.pdf</uri>.</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latif</surname> <given-names>IA</given-names>
</name>
<name>
<surname>Mohamed</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Sharifuddin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Abdullah</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Ismail</surname> <given-names>MM</given-names>
</name>
</person-group>. <article-title>A Comparative Analysis of Global Halal Certification Requirements</article-title>. <source>J Food Prod Mark</source> (<year>2014</year>) <volume>20</volume>(<issue>sup1</issue>):<fpage>85</fpage>&#x2013;<lpage>101</lpage>. doi: <pub-id pub-id-type="doi">10.1080/10454446.2014.921869</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Indonesian Ulema Council</collab>
</person-group>. <source>Fatwa Majelis Ulama Indonesia Nomor&#xa0;: 02 Tahun 2021 Tentang Produk Vaksin Covid-19 Dari Sinovac Life Sciences, Co. Ltd China Dan PT Biofarma</source> (<year>2021</year>). Available at: <uri xlink:href="https://mui.or.id/produk/fatwa/29485/fatwa-mui-no-02-tahun-2021-tentang-produk-vaksin-covid-19-dari-sinovac-life-sciences-co-ltd-china-dan-pt-biofarma/">https://mui.or.id/produk/fatwa/29485/fatwa-mui-no-02-tahun-2021-tentang-produk-vaksin-covid-19-dari-sinovac-life-sciences-co-ltd-china-dan-pt-biofarma/</uri>.</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Indonesian Ulema Council</collab>
</person-group>. <source>Fatwa MUI No 14 Tahun 2021 Tentang Hukum Penggunaan Vaksin Covid-19 Produk Astrazeneca</source> (<year>2021</year>). Available at: <uri xlink:href="https://mui.or.id/produk/fatwa/29883/fatwa-mui-hukum-penggunaan-vaksin-covid-19-produk-astrazeneca/">https://mui.or.id/produk/fatwa/29883/fatwa-mui-hukum-penggunaan-vaksin-covid-19-produk-astrazeneca/</uri>.</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Tempo</collab>
</person-group>. <source>We Need Science, Not Fatwas</source> (<year>2021</year>). Available at: <uri xlink:href="https://en.tempo.co/read/1446020/we-need-science-not-fatwas">https://en.tempo.co/read/1446020/we-need-science-not-fatwas</uri>.</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Rochmyaningsih</surname> <given-names>D</given-names>
</name>
</person-group>. <source>Indonesian &#x2018;Vaccine Fatwa&#x2019;sends Measles Immunization Rates Plummeting. Science Magazine</source> (<year>2018</year>). Available at: <uri xlink:href="https://www.science.org/news/2018/11/indonesian-vaccine-fatwa-sends-measles-immunization-rates-plummeting">https://www.science.org/news/2018/11/indonesian-vaccine-fatwa-sends-measles-immunization-rates-plummeting</uri>.</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>World Health Organization RO for the EM</collab>
</person-group>. <source>Statement Arising From a Seminar Held by the Islamic Organization for Medical Sciences on &#x2018;The Judicially Prohibited and Impure Substances in Foodstuff and Drugs&#x2019;</source> (<year>2001</year>). Available at: <uri xlink:href="http://www.immunize.org/concerns/porcine.pdf">www.immunize.org/concerns/porcine.pdf</uri>.</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jahangir</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mehmood</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Saifullah</surname>
</name>
<name>
<surname>Bashir</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Mehboob</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ali</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Halal Status of Ingredients After Physicochemical Alteration (Istihalah)</article-title>. <source>Trends Food Sci Technol</source> (<year>2016</year>) <volume>47</volume>:<fpage>78</fpage>&#x2013;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tifs.2015.10.011</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rochmyaningsih</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Indonesian Fatwa Causes Immunization Rates to Drop</article-title>. <source>Sci (New York NY) United States</source> (<year>2018</year>) <volume>362</volume>:<page-range>628&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.362.6415.628</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosman</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Fadzillah</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Samat</surname> <given-names>AB</given-names>
</name>
</person-group>. <article-title>Fatwa Debate on Porcine Derivatives in Vaccine From the Concept of Physical and Chemical Transformation (Istihalah) in Islamic Jurisprudence and Science</article-title>. <source>J Crit Rev</source> (<year>2020</year>) <volume>7</volume>(<issue>7</issue>):<page-range>1037&#x2013;45</page-range>. doi: <pub-id pub-id-type="doi">10.31838/jcr.07.07.189</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abubakar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hukum Vaksin</surname> <given-names>MR</given-names>
</name>
</person-group>. <article-title>Teori Istihalah Dan Istihlak Versus Fatwa MUI</article-title>. <source>Media Syari&#x2019;ah: Wahana Kajian Hukum Islam Dan Pranata Sosial</source> (<year>2021</year>) <volume>23</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.22373/jms.v23i1.8485</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sholeh</surname> <given-names>MAN</given-names>
</name>
<name>
<surname>Helmi</surname> <given-names>MI</given-names>
</name>
</person-group>. <article-title>The COVID-19 Vaccination: Realization on Halal Vaccines for Benefits</article-title>. <source>Samarah: J Hukum Keluarga Dan Hukum Islam</source> (<year>2021</year>) <volume>5</volume>(<issue>1</issue>):<page-range>174&#x2013;90</page-range>. doi: <pub-id pub-id-type="doi">10.22373/sjhk.v5i1.9769</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corey</surname> <given-names>L</given-names>
</name>
<name>
<surname>Mascola</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Fauci</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Collins</surname> <given-names>FS</given-names>
</name>
</person-group>. <article-title>A Strategic Approach to COVID-19 Vaccine R&amp;D</article-title>. <source>Sci (New York NY)</source> (<year>2020</year>) <volume>368</volume>(<issue>6494</issue>):<page-range>948&#x2013;50</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.abc5312</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Kasule</surname> <given-names>O</given-names>
</name>
</person-group>. <source>Islamic Legal Guidelines on Polio Vaccination in India. 16th Session of the Fiqh Academy of India</source> (<year>2007</year>). Available at: <uri xlink:href="http://omarkasule-04.tripod.com/id1406.html">http://omarkasule-04.tripod.com/id1406.html</uri>.</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>US FDA</collab>
</person-group>. <article-title>Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications</article-title>. In: <source>Center for Biologics Evaluation and Research</source> (<year>2010</year>). <publisher-loc>White Oak, Maryland</publisher-loc>: <publisher-name>Food and Drug Administration</publisher-name>. Available at: <uri xlink:href="https://www.fda.gov/media/78428/download">https://www.fda.gov/media/78428/download</uri>.</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>US FDA</collab>
</person-group>. <source>Facts About the Current Good Manufacturing Practices (Cgmps)</source> (<year>2015</year>). Available at: <uri xlink:href="https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps">https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps</uri>.</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>. <article-title>Good Manufacturing Practices for Biological Products</article-title>. In: <source>Who Technical Report Series</source>, vol. <volume>822</volume>. (<year>1992</year>). p. <page-range>20&#x2013;9</page-range>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>. Available at: <uri xlink:href="https://www.who.int/biologicals/publications/trs/areas/vaccines/gmp/WHO_TRS_822_A1.pdf?ua=1">https://www.who.int/biologicals/publications/trs/areas/vaccines/gmp/WHO_TRS_822_A1.pdf?ua=1</uri>.</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Code US, Law P</collab>
</person-group>. <article-title>21 C.F.R. &#xa7; 610</article-title>. In: <source>Code of Federal Regulations</source> (<year>2013</year>). <publisher-loc>Washington, D.C</publisher-loc>: <publisher-name>Office of the Federal Register</publisher-name>. Available at: <uri xlink:href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-610">https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-610</uri>.</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Code US, Law P</collab>
</person-group>. <article-title>9 C.F.R. &#xa7; 113</article-title>. In: <source>Code of Federal Regulations</source> (<year>2017</year>). <publisher-loc>Washington, D.C</publisher-loc>: <publisher-name>Office of the Federal Register</publisher-name>. Available at: <uri xlink:href="https://www.ecfr.gov/current/title-9/chapter-I/subchapter-E/part-113">https://www.ecfr.gov/current/title-9/chapter-I/subchapter-E/part-113</uri>.</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>Institute of Medicine (US) Forum on Microbial Threats</collab>
</person-group>. <article-title>Addressing Foodborne Threats to Health: Policies, Practices, and Global Coordination: Workshop Summary</article-title>. In: <source>Reporting Foodborne Threats: The Case of Bovine Sp</source>. <publisher-loc>Washington (DC</publisher-loc>: <publisher-name>National Academies Press (US</publisher-name> (<year>2006</year>). Available at: <uri xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK57084/">https://www.ncbi.nlm.nih.gov/books/NBK57084/</uri>. National Academies Press (US).</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Fletcher</surname> <given-names>T</given-names>
</name>
<name>
<surname>Harris</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Safety Drives Innovation in Animal-Component-Free Cell-Culture Media Technology</article-title>. In: <source>Safety</source> (<year>2016</year>). <publisher-loc>Iselin, New Jersey</publisher-loc>: <publisher-name>BioPharm International</publisher-name>. Available at: <uri xlink:href="http://www.processdevelopmentforum.com/articles/safety-drives-innovation-in-animal-component-free-cell-culture-media-technology/">http://www.processdevelopmentforum.com/articles/safety-drives-innovation-in-animal-component-free-cell-culture-media-technology/</uri>.</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenbaum</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Escaping Catch-22 &#x2014; Overcoming Covid Vaccine Hesitancy</article-title>. <source>New Engl J Med</source> (<year>2021</year>) <volume>384</volume>(<issue>14</issue>):<page-range>1367&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMms2101220</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>